Sarepta Therapeutics (SRPT) Net Income towards Common Stockholders (2010 - 2026)

Sarepta Therapeutics' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $331.0 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 173.96% year-over-year to $331.0 million in Q1 2026; TTM through Mar 2026 was $65.1 million, a 126.21% increase from a year earlier, with the FY2025 full-year figure at -$713.4 million, down 403.27% from the prior year.
• Net Income towards Common Stockholders improved to $331.0 million in Q1 2026 per SRPT's latest filing, from -$282.9 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $331.0 million in Q1 2026 and bottomed at -$516.8 million in Q1 2023.
• The 5-year median for Net Income towards Common Stockholders is -$23.9 million (2023), against an average of -$55.7 million.
• Biggest YoY gain for Net Income towards Common Stockholders was 2796.15% in 2025; the steepest drop was 1324.47% in 2025.
• Year by year, Net Income towards Common Stockholders stood at $329.3 million in 2022, then slumped by 86.19% to $45.5 million in 2023, then soared by 249.09% to $158.8 million in 2024, then plunged by 278.14% to -$282.9 million in 2025, then jumped by 217.0% to $331.0 million in 2026.
• Per Business Quant, the three latest SRPT Net Income towards Common Stockholders figures stand at $331.0 million (Q1 2026), -$282.9 million (Q4 2025), and -$179.9 million (Q3 2025).